Bronchiectasis Exacerbation

Acute worsening of bronchiectasis — Pseudomonas infection, recurrent bacterial infections, or mucus plugging causing increased symptoms and inflammatory burden

Symptoms / Associated Sx

  • Increased dyspnea beyond baseline

  • Increase in sputum volume, purulence, or change in color (key exacerbation marker)

  • Hemoptysis (blood-streaked to moderate — from inflamed bronchial mucosa)

  • Fever (less consistently present than in pneumonia)

  • Increased fatigue, decreased exercise tolerance

  • Crackles and wheeze on exam (bilateral or localized)

Denies

  • Acute onset in previously healthy lung (raises first diagnosis; bronchiectasis requires prior damage)

  • Fever + focal consolidation without chronic sputum history (raises CAP over bronchiectasis exacerbation)

  • Blood-tinged sputum without prior bronchiectasis history (raises malignancy or TB)

Social History (SHx)

Underlying etiology of bronchiectasis (prior TB, post-infectious — childhood pertussis/measles, ABPA, primary ciliary dyskinesia, cystic fibrosis, COPD, RA, IBD), prior sputum cultures and organisms (especially Pseudomonas aeruginosa, MRSA, Aspergillus, NTM), prior antibiotic courses and sensitivities, airway clearance regimen compliance, mucus-thinning agents used, exacerbation frequency (defines severity).

Main Etiology

  • Pseudomonas aeruginosa (most common in moderate-severe bronchiectasis; associated with worse prognosis)

  • Haemophilus influenzae (most common in mild-moderate bronchiectasis)

  • Moraxella catarrhalis, Streptococcus pneumoniae

  • MRSA (prior culture or healthcare-associated)

  • NTM (Mycobacterium avium complex — MAC; chronic indolent course)

  • Viral URI trigger

  • Mucus plugging (without infection)

Most Common DDx

  • Community-acquired pneumonia (acute onset without chronic sputum history; lobar consolidation on CXR; responds to short-course standard CAP antibiotics)

  • COPD exacerbation (heavy smoking history; obstruction predominant; hyperinflation on CXR; may coexist with bronchiectasis)

  • Allergic bronchopulmonary aspergillosis (ABPA) exacerbation (central bronchiectasis; eosinophilia; elevated IgE >1000 IU/mL; Aspergillus skin test positive; responds to steroids)

  • NTM pulmonary disease (insidious onset; Lady Windermere syndrome — right middle lobe + lingular; AFB smear/culture; CT shows nodules + bronchiectasis)

  • Lung abscess (cavitary lesion; prolonged fever; anaerobes; aspiration risk)

  • Cystic fibrosis exacerbation (young patient; elevated sweat chloride; Pseudomonas/MRSA/Burkholderia cepacia)

DATA

  • CBC (leukocytosis; eosinophilia → ABPA)

  • BMP (renal function for antibiotic dosing — aminoglycosides)

  • CRP/ESR (inflammation; treatment response marker)

  • Sputum Gram stain + culture (critical — identify organism; compare to prior cultures; sensitivities guide therapy)

  • AFB smear × 3 + culture (NTM/TB — if clinically suspected)

  • Total IgE + Aspergillus-specific IgE + skin test (ABPA screening if eosinophilia)

  • CXR (bronchiectatic changes; new infiltrate superimposed; mucus plugging; atelectasis)

  • CT chest HRCT (gold standard for bronchiectasis — tram-track sign, signet ring sign; new consolidation; extent of disease)

  • Spirometry (FEV1 decline — disease progression monitor; defer during acute)

  • Sweat chloride / CFTR genotyping (if cystic fibrosis suspected)

Home Meds

  • Nebulized hypertonic saline (7%) — mucociliary clearance; continue

  • Dornase alfa (Pulmozyme) — CF bronchiectasis; continue

  • Long-term macrolide (azithromycin 250 mg 3× weekly — anti-inflammatory + immunomodulatory; continue)

  • Inhaled antibiotics (tobramycin, colistin, aztreonam — chronic Pseudomonas suppression; continue or escalate)

  • Bronchodilators (SABA/LABA — continue)

  • Prior IV antibiotics and sensitivities (essential for empiric selection in exacerbation)

Plan

  • Sputum culture BEFORE antibiotics (essential; prior culture results guide empiric choice)

  • Antibiotic selection (based on prior culture results and risk factors):

    • No prior Pseudomonas / low-risk: Amoxicillin-clavulanate 875 mg PO BID × 14 days OR Levofloxacin 750 mg PO/IV daily × 14 days

    • Known or suspected Pseudomonas aeruginosa: Ciprofloxacin 750 mg PO BID × 14 days (mild-moderate); IV anti-pseudomonal needed if severe: Piperacillin-tazobactam 3.375 g IV q6h OR Cefepime 2 g IV q8h OR Meropenem 1 g IV q8h (MDR Pseudomonas) × 14 days

    • MRSA: Add Vancomycin 15–20 mg/kg IV q8–12h OR Linezolid 600 mg PO/IV BID

    • Duration: 14 days minimum for Pseudomonas; 7–10 days for non-Pseudomonas

  • Airway clearance (cornerstone of management — must not be omitted):

    • Chest physiotherapy (manual or mechanical — vest therapy, oscillating PEP)

    • Hypertonic saline 7% nebulized q12h (thins secretions; improves mucociliary clearance)

    • Active cycle of breathing technique (ACBT) — with respiratory therapist

    • Bronchodilators before airway clearance (albuterol 2.5 mg nebulized)

  • Supplemental O2 if hypoxic

  • ABPA exacerbation: Prednisone 0.5 mg/kg/day PO × 4–6 weeks; itraconazole 200 mg PO BID as steroid-sparing; close monitoring of IgE as treatment response marker

  • NTM disease (MAC) — 3-drug regimen (macrolide + rifampicin + ethambutol × 12+ months after culture conversion) — ID/pulmonology directed

  • Daily CBC, BMP; CRP trending; serial sputum cultures at 48–72h; adjust antibiotics per sensitivities

  • Pulmonology consult; ID consult for NTM/MDR Pseudomonas; respiratory therapy

  • PT/OT — breathing exercises; energy conservation

  • Discharge: Complete 14-day antibiotic course; resume airway clearance regimen; continue nebulized hypertonic saline; long-term macrolide if ≥3 exacerbations/year; pulmonology follow-up 2–4 weeks; consider long-term inhaled tobramycin/colistin for Pseudomonas-colonized; HRCT follow-up to assess disease progression; influenza and pneumococcal vaccination

Red Flags

  • Massive hemoptysis (>200 mL) → bronchial artery embolization immediately (see hemoptysis section)

  • Severe hypoxia + bilateral infiltrates in bronchiectasis → secondary ARDS or severe pneumonia → ICU; lung-protective ventilation

  • MDR Pseudomonas or Burkholderia cepacia (CF patients) → ID consult urgently; combination IV antibiotic therapy; infection control precautions (Burkholderia cepacia is highly transmissible between CF patients)

  • NTM disease not responding to antibiotics → consider drug resistance; bronchoscopy + BAL for repeat sensitivities

  • Progressive FEV1 decline despite maximal therapy → lung transplant evaluation

Senior IM Resident Pearls

  • Prior culture results are essential for empiric antibiotic selection in bronchiectasis — always review prior sputum cultures before prescribing; Pseudomonas organisms are drug-resistant and 14 days of IV therapy is often required

  • ABPA diagnostic criteria: Asthma + elevated total IgE (>1000 IU/mL) + Aspergillus IgE + central bronchiectasis + eosinophilia + pulmonary infiltrates — steroids are first-line; azoles reduce antigen burden and steroid requirements

  • Long-term macrolide therapy (azithromycin 3× weekly) reduces exacerbation frequency by ~30% in non-CF bronchiectasis (BOS-2 trial); reduces inflammation via immunomodulation; screen for NTM BEFORE starting (macrolides cause NTM resistance)

  • Signet ring sign on HRCT = bronchus diameter greater than adjacent pulmonary artery — pathognomonic of bronchiectasis; tram-track sign = parallel lines of bronchiectatic wall on axial view

  • Common mistake: Not sending sputum culture before empiric antibiotics — without culture data, Pseudomonas resistance pattern cannot be predicted; sputum culture is mandatory before antibiotic initiation in every bronchiectasis exacerbation